‘Extraordinary growth’ on the cards for cancer immunotherapies
The market for cancer immunotherapies is set to swell more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, with a rapid compound annual growth rate of 23.9 percent, predicts business intelligence provider GBI Research.
Read More
